

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2021/0198346 A1 OELKRUG et al.

Jul. 1, 2021 (43) **Pub. Date:**

(54) TREATMENT OF IMMUNE DISEASES BY MEANS OF THE ANTIBODY-MEDIATED NEUTRALIZATION OF SPECIFIC INTESTINAL BACTERIA

(71) Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten

Forschung e.V., München (DE)

(72) Inventors: Christopher OELKRUG, Aschenberg

(DE); Daniel Christoph WAGNER, Mainz (DE); Armin BRAUN, Isernhagen (DE); Christina HESSE, Osterode (DE)

(21) Appl. No.: 17/265,506

PCT Filed: Aug. 2, 2019 (22)

(86) PCT No.: PCT/EP2019/070910

§ 371 (c)(1),

(2) Date: Feb. 2, 2021

(30)Foreign Application Priority Data

(DE) 10 2018 213 030.2

Publication Classification

(51)Int. Cl. C07K 16/12

(2006.01)

A61K 45/06

(2006.01)

U.S. Cl. CPC C07K 16/1282 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01);

C07K 2317/76 (2013.01)

(57)ABSTRACT

An antibody or an antigen-binding fragment thereof binds to an antigen of the bacterium Candidatus savagella and inhibits the adhesion of the bacterium to intestinal epithelial cells; and/or depletes the bacterium. A drug has the antibody or an antigen-binding fragment thereof. A kit has the antibody or an antigen-binding fragment thereof for reduction of Th 17 cell proliferation, Th 17 cell differentiation or Th 17 cell activity and/or inhibition of the formation of antibodies against endogenous antigens by B cells. The kit can contain an antibiotic. A method for producing the antibody involves immunizing chickens with an immunogenic peptide from an antigen of the bacterium Candidatus savagella, and recovering and purifying the antibodies formed in the chickens or in an egg laid by said chickens. A method for producing the drug involves producing the antibody or an antigen-binding fragment thereof, and formulating the antibody or an antigen-binding fragment thereof as a drug.

Specification includes a Sequence Listing.

